Bicycle Therapeutics (NASDAQ:BCYC) Announces Earnings Results, Beats Estimates By $0.06 EPS

Bicycle Therapeutics (NASDAQ:BCYC) issued its quarterly earnings data on Thursday. The company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.06, Briefing.com reports. Bicycle Therapeutics had a negative net margin of 417.88% and a negative return on equity of 32.80%. The company had revenue of $2.68 million during the quarter, compared to the consensus estimate of $6.82 million. During the same quarter in the previous year, the firm posted ($1.26) earnings per share. Bicycle Therapeutics’s revenue for the quarter was down 50.0% compared to the same quarter last year.

Bicycle Therapeutics Trading Up 0.7 %

NASDAQ:BCYC traded up $0.16 during trading hours on Friday, reaching $23.60. 169,480 shares of the company were exchanged, compared to its average volume of 352,821. Bicycle Therapeutics has a 52-week low of $12.54 and a 52-week high of $28.67. The stock has a 50 day simple moving average of $24.18 and a 200 day simple moving average of $23.11. The firm has a market cap of $1.12 billion, a price-to-earnings ratio of -6.19 and a beta of 0.89. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.77 and a quick ratio of 14.77.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Bicycle Therapeutics in a research report on Monday, September 9th. JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 price target on shares of Bicycle Therapeutics in a research note on Monday, September 16th. Needham & Company LLC reissued a “buy” rating and issued a $38.00 target price on shares of Bicycle Therapeutics in a research note on Thursday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $35.00 price target on shares of Bicycle Therapeutics in a research report on Friday. Finally, B. Riley downgraded shares of Bicycle Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the company from $33.00 to $28.00 in a report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.56.

Insider Transactions at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 3,212 shares of the firm’s stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $22.26, for a total transaction of $71,499.12. Following the completion of the sale, the chief executive officer now directly owns 380,864 shares of the company’s stock, valued at approximately $8,478,032.64. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 4,584 shares of company stock valued at $102,040 over the last 90 days. Corporate insiders own 8.50% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.